Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors

Biochemistry

Volumn 48, Issue 10, 2009, Pages 2180-2191

  Reis, Carlos R ^a   Van Der Sloot, Almer M ^b   Szegezdi, Eva ^c   Natoni, Alessandro ^c   Tur, Vicente ^b   Cool, Robbert H ^a,d   Samali, Afshin ^c   Serrano, Luis ^e   Quax, Wim J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d Triskel Therapeutics BV   (Netherlands)

^e UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER AGENTS; ANTITUMOR PROPERTIES; APOPTOSIS; CANCER CELLS; DEATH RECEPTORS; IN-VITRO; INDUCED APOPTOSIS; NECROSIS FACTORS; THERAPEUTIC AGENTS; WILD TYPES;

AMINES; AMINO ACIDS; ORGANIC ACIDS; TUMORS;

CELL DEATH;

AMINO ACID; ANTINEOPLASTIC AGENT; ARGININE; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GLYCINE; LIGAND; LYSINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; NECROSIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; WILD TYPE;

AMINO ACID CHLOROMETHYL KETONES; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARGININE; BINDING, COMPETITIVE; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; DATABASES, PROTEIN; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCINE; HUMANS; HYDROGEN BONDING; LYSINE; MODELS, MOLECULAR; PEPTIDE HYDROLASES; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; THERMODYNAMICS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 64349116531     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi801927x     Document Type: Article

References (34)

1. Ashkenazi, A. (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 19, 325-331.
2. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.
3. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., and Ashkenazi, A. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7, 383-385.
4. LeBlanc, H. N., and Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66-75.
5. Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., and Hood, L. (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7, 821-830.
6. Kuang, A. A., Diehl, G. E., Zhang, J., and Winoto, A. (2000) FADD is required for DR4-and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J. Biol. Chem. 275, 25065-25068.
7. Schneider, P., Thome, M., Burns, K., Bodmer, J. L., Hofmann, K., Kataoka, T., Holler, N., and Tschopp, J. (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7, 831-836.
8. Bodmer, J. L., Holler, N., Reynard, S., Vinciguerra, P., Schneider, P., Juo, P., Blenis, J., and Tschopp, J. (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2, 241-243.
9. Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., and Ashkenazi, A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620.
10. Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., and Walczak, H. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599-609.
11. Kimberley, F. C., and Screaton, G. R. (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res. 14, 359-372.
12. Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., Screaton, G., Lenardo, M. J., and Chan, F. K (2005) Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 102, 18099-18104.
13. Merino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., and Micheau, O. (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell. Biol. 26, 7046-7055.
14. Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., and Zhou, T. (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7, 954-960.
15. Almasan, A., and Ashkenazi, A. (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-348.
16. Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., Deforge, L., Pai, R., Hymowitz, S. G., and Ashkenazi, A. (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280, 2205-2212.
17. Szegezdi, E., Cahill, S., Meyer, M., O'Dwyer, M., and Samali, A. (2006) TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br. J. Cancer 94, 398-406.
18. Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., McLaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., Williams, W. V., and Doyle, M. L. (2000) Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275, 23319-23325.
19. van der Sloot, A. M., Tur, V., Szegezdi, E., Mullally, M. M., Cool, R. H., Samali, A., Serrano, L., and Quax, W. J. (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 8634-8639.
20. MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N., Kennedy, D. B., Dyer, M. J., and Cohen, G. M. (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 12, 773-782.
21. MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J., and Cohen, G. M. (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65, 11265-11270.
22. Kortemme, T., Joachimiak, L. A., Bullock, A. N., Schuler, A. D., Stoddard, B. L., and Baker, D. (2004) Computational redesign of protein-protein interaction specificity. Nat. Struct. Mol. Biol. 11, 371-379.
23. Reina, J., Lacroix, E., Hobson, S. D., Fernandez-Ballester, G., Rybin, V., Schwab, M. S., Serrano, L., and Gonzalez, C. (2002) Computer-aided design of a PDZ domain to recognize new target sequences. Nat. Struct. Biol. 9, 621-627.
24. Shifman, J. M., and Mayo, S. L. (2002) Modulating calmodulin binding specificity through computational protein design. J. Mol. Biol. 323, 417-423.
25. Tur, V., van der Sloot, A. M., Reis, C. R., Szegezdi, E., Cool, R. H., Samali, A., Serrano, L., and Quax, W. J. (2008) DR4 selective TRAIL variants obtained by structure based design. J. Biol. Chem. 29, 20560-20568.
26. Mongkolsapaya, J., Grimes, J. M., Chen, N., Xu, X. N., Stuart, D. I., Jones, E. Y., and Screaton, G. R. (1999) Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol. 6, 1048-1053.
27. Guerois, R., Nielsen, J. E., and Serrano, L. (2002) Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 320, 369-387.
28. Schymkowitz, J. W., Rousseau, F., Martins, I. C., Ferkinghoff-Borg, J., Stricher, F., and Serrano, L. (2005) Prediction of water and metal binding sites and their affinities by using the Fold-X force field. Proc. Natl. Acad. Sci. U.S.A. 102, 10147-10152.
29. Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., and Kelley, R. F. (2000) A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39, 633-640.
30. van der Sloot, A. M., Mullally, M. M., Fernandez-Ballester, G., Serrano, L., and Quax, W. J. (2004) Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign. Protein Eng. Des. Sel. 17, 673-680.
31. Cha, S. S., Sung, B. J., Kim, Y. A., Song, Y. L., Kim, H. J., Kim, S., Lee, M. S., and Oh, B. H. (2000) Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275, 31171-31177.
32. Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., and de Vos, A. M. (1999) Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4, 563-571.
33. Thomas, L. R., Johnson, R. L., Reed, J. C., and Thorburn, A. (2004) The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J. Biol. Chem. 279, 52479-52486.
34. van Geelen, C. M., de Vries, E. G., Le, T. K., van Weeghel, R. P., and de Jong, S. (2003) Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br. J. Cancer 89, 363-373.